U.S. Molecular Diagnostics For STD Market (2025 - 2033) Size, Share & Trends Analysis Report By Product (Instruments & Services, Consumables), By Application (Chlamydia Testing, Syphilis Testing), By Technology, And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation and Scope
                    1.2. Market Definitions
                    1.3. Research Methodology
                        1.3.1. Information Procurement
                        1.3.2. Information or Data Analysis
                        1.3.3. Market Formulation & Data Visualization
                        1.3.4. Data Validation & Publishing
                    1.4. Research Scope and Assumptions
                        1.4.1. List of Data Sources
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Outlook
                    2.3. Competitive Insights
Chapter 3. U.S. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Variables, Trends, & Scope
                    3.1. Market Introduction/Lineage Outlook
                    3.2. Market Size and Growth Prospects (USD Million)
                    3.3. Market Dynamics
                        3.3.1. Market Drivers Analysis
                        3.3.2. Market Restraints Analysis
                    3.4. U.S. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Analysis Tools
                        3.4.1. Porter’s Analysis
                            3.4.1.1. Bargaining power of the suppliers
                            3.4.1.2. Bargaining power of the buyers
                            3.4.1.3. Threats of substitution
                            3.4.1.4. Threats from new entrants
                            3.4.1.5. Competitive rivalry
                        3.4.2. PESTEL Analysis
                            3.4.2.1. Political landscape
                            3.4.2.2. Economic and Social landscape
                            3.4.2.3. Technological landscape
                            3.4.2.4. Environmental landscape
                            3.4.2.5. Legal landscape
Chapter 4. U.S. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Product Estimates & Trend Analysis
                    4.1. Segment Dashboard
                    4.2. U.S. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Product Movement Analysis, 2024 & 2033 (USD Million)
                    4.3. Instruments & Services
                        4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                    4.4. Consumables (Reagents and kits)
                        4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                    4.5. Software
                        4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. U.S. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Application Estimates & Trend Analysis
                    5.1. Segment Dashboard
                    5.2. U.S. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Application Movement Analysis, 2024 & 2033 (USD Million)
                    5.3. CT/NG testing
                        5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                    5.4. Syphilis testing
                        5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                    5.5. Gonorrhea testing
                        5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                    5.6. HSV testing
                        5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                    5.7. HPV testing
                        5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                    5.8. HIV testing
                        5.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                    5.9. Trichomonas
                        5.9.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                    5.10. Ureaplasma + Mycoplasma
                        5.10.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                    5.11. Others
                        5.11.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. U.S. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Technology Estimates & Trend Analysis
                    6.1. Segment Dashboard
                    6.2. U.S. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Technology Movement Analysis, 2024 & 2033 (USD Million)
                    6.3. Laboratory Testing
                        6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                        6.3.2. Commercial/Private Labs
                            6.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                        6.3.3. Public Health Labs
                            6.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                    6.4. PoC testing
                        6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Competitive Landscape
                    7.1. Recent Developments & Impact Analysis by Key Market Participants
                    7.2. Company Categorization
                    7.3. Company Heat Map Analysis
                    7.4. Company Profiles
                        7.4.1. BD
                            7.4.1.1. Participant’s Overview
                            7.4.1.2. Financial Performance
                            7.4.1.3. Product Benchmarking
                            7.4.1.4. Recent Developments/ Strategic Initiatives
                        7.4.2. F. Hoffmann-La Roche Ltd
                            7.4.2.1. Participant’s Overview
                            7.4.2.2. Financial Performance
                            7.4.2.3. Product Benchmarking
                            7.4.2.4. Recent Developments/ Strategic Initiatives
                        7.4.3. Hologic Inc.
                            7.4.3.1. Participant’s Overview
                            7.4.3.2. Financial Performance
                            7.4.3.3. Product Benchmarking
                            7.4.3.4. Recent Developments/ Strategic Initiatives
                        7.4.4. Abbott
                            7.4.4.1. Participant’s Overview
                            7.4.4.2. Financial Performance
                            7.4.4.3. Product Benchmarking
                            7.4.4.4. Recent Developments/ Strategic Initiatives
                        7.4.5. Cepheid (Danaher)
                            7.4.5.1. Participant’s Overview
                            7.4.5.2. Financial Performance
                            7.4.5.3. Product Benchmarking
                            7.4.5.4. Recent Developments/ Strategic Initiatives
                        7.4.6. Qiagen
                            7.4.6.1. Participant’s Overview
                            7.4.6.2. Financial Performance
                            7.4.6.3. Product Benchmarking
                            7.4.6.4. Recent Developments/ Strategic Initiatives
                        7.4.7. OraSure Technologies, Inc.
                            7.4.7.1. Participant’s Overview
                            7.4.7.2. Financial Performance
                            7.4.7.3. Product Benchmarking
                            7.4.7.4. Recent Developments/ Strategic Initiatives
                        7.4.8. Bio-Rad Laboratories, Inc.
                            7.4.8.1. Participant’s Overview
                            7.4.8.2. Financial Performance
                            7.4.8.3. Product Benchmarking
                            7.4.8.4. Recent Developments/ Strategic Initiatives
                        7.4.9. bioMérieux SA
                            7.4.9.1. Participant’s Overview
                            7.4.9.2. Financial Performance
                            7.4.9.3. Product Benchmarking
                            7.4.9.4. Recent Developments/ Strategic Initiatives
                        7.4.10. Thermo Fisher Scientific, Inc.
                            7.4.10.1. Participant’s Overview
                            7.4.10.2. Financial Performance
                            7.4.10.3. Product Benchmarking
                            7.4.10.4. Recent Developments/ Strategic Initiatives
                        7.4.11. Seegene Inc.
                            7.4.11.1. Participant’s Overview
                            7.4.11.2. Financial Performance
                            7.4.11.3. Product Benchmarking
                            7.4.11.4. Recent Developments/ Strategic Initiatives
                        7.4.12. DiaSorin S.p.A
                            7.4.12.1. Participant’s Overview
                            7.4.12.2. Financial Performance
                            7.4.12.3. Product Benchmarking
                            7.4.12.4. Recent Developments/ Strategic Initiatives

List of Tables

Table 1 List of key distributors and channel partners
Table 2 List of key emerging companies’/technology disruptors/innovators
Table 3 U.S. Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
Table 4 U.S. Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
Table 5 U.S. Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research
Fig. 4 Value-chain-based sizing & forecasting
Fig. 5 QFD modelling for market share assessment
Fig. 6 Market formulation & validation
Fig. 7 Commodity flow analysis
Fig. 8 Market outlook
Fig. 9 Segment snapshot-1
Fig. 10 Segment snapshot-2
Fig. 11 Competitive landscape snapshot
Fig. 12 Market trends & outlook
Fig. 13 Porter’s five force analysis
Fig. 14 PESTEL analysis
Fig. 15 U.S. molecular diagnostics for Sexually Transmitted Diseases (STDs) market: Product outlook key takeaways
Fig. 16 U.S. molecular diagnostics for Sexually Transmitted Diseases (STDs) market: Product movement analysis
Fig. 17 Instruments & Services market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 18 Consumables (Reagents and kits) market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 19 Software market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 20 U.S. molecular diagnostics for Sexually Transmitted Diseases (STDs) market: Application outlook key takeaways
Fig. 21 U.S. molecular diagnostics for Sexually Transmitted Diseases (STDs) market: Application movement analysis
Fig. 22 CT/NG testing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 23 Syphilis testing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 24 Gonorrhea testing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 25 HSV testing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 26 HPV testing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 27 HIV testing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 28 Trichomonas market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 29 Ureaplasma + Mycoplasma market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 30 Others market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 31 U.S. molecular diagnostics for Sexually Transmitted Diseases (STDs) market: Technology outlook key takeaways
Fig. 32 U.S. molecular diagnostics for Sexually Transmitted Diseases (STDs) market: Technology movement analysis
Fig. 33 Laboratory Testing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 34 Commercial/Private Labs market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 35 Public Health Labs market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 36 PoC testing market estimates and forecasts, 2021 - 2033 (USD Million)